Drug Type Biosimilar, Monoclonal antibody |
Synonyms Trastuzumab Biosimilar (Biocon Ltd.), 曲妥珠单抗生物类似药(Biocon Ltd.) |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hormone receptor negative HER2 positive breast cancer | ID | 30 Nov 2022 | |
Metastatic breast cancer | ID | 30 Nov 2022 | |
Stomach Cancer | ID | 30 Nov 2022 |